The PCSK9 inhibitors Praluent (alirocumab; Sanofi/Regeneron) and Repatha (evolocumab; Amgen/Astellas) have experienced minimal uptake in the dyslipidemia market since their launches in 2015.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!